Australian recommendations for the management of hepatocellular carcinoma

In reply: We welcome the comments raised by Braillon1 regarding the contribution of smoking to the risk of hepatocellular carcinoma (HCC).

1 Alfred Health, Melbourne, VIC
2 Monash University, Melbourne, VIC
3 AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Sydney, NSW
4 University of Sydney, Sydney, NSW
5 University of New South Wales, Sydney, NSW

Correspondence: J.Lubel@alfred.org.au

Competing interests:

No relevant disclosures.

1. Braillon A. Australian recommendations for the management of hepatocellular carcinoma: a consensus statement [letter]. Med J Aust 2021; 215: 000–000.
2. Lubel JS, Roberts SK, Strasser SI, et al. Australian recommendations for the management of hepatocellular carcinoma: a consensus statement. Med J Aust 2021; 214: 475–483. https://www.mja.com.au/journal/2021/214/10/australian-recommendations-management-hepatocellular-carcinoma-consensus
3. Australian Institute of Health and Welfare 2020. National Drug Strategy Household Survey 2019 [Cat. No. PHE 270]. Canberra: AIHW. 2020. https://www.aihw.gov.au/reports/illicit-use-of-drugs/national-drug-strategy-household-survey-2019/contents/summary (viewed Aug 2021).
4. Bataller R. Time to ban smoking in patients with chronic liver diseases. Hepatology 2006; 44: 1394–1396.
5. Jones J, Hunter D. Consensus methods for medical and health services research. BMJ 1995; 311: 376–380.
6. Raine R, Sanderson C, Black N. Developing clinical guidelines: a challenge to current methods. BMJ 2005; 331: 631–633.

Online responses are no longer available. Please refer to our instructions for authors page for more information.